Article Text
Abstract
Direct-to-consumer advertising is banned in Australia, and instead pharmaceutical companies use disease awareness campaigns as a strategy to raise public awareness of conditions for which the company produces a treatment. This practice has been justified by promoting individual autonomy and public health, but it has attracted criticism regarding medicalisation of normal health and ageing, and exaggeration of the severity of the condition in question, imbalanced reporting of risks and benefits, and damaging the patient–clinician relationship. While there are benefits of disease awareness promotion, there is another possible adverse consequence that has not yet been rigorously considered: the possibility of inducing a nocebo response via the campaign. We will discuss the creation of a nocebo response in this context.
- public health ethics
- applied and professional ethics
- drugs and drug industry
Statistics from Altmetric.com
Footnotes
Contributors SB performed the literature search and authored the paper. DH provided the initial idea for the paper and reviewed the paper throughout writing and prior to submission.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review
- PO104 Placebo and nocebo responses in rls: a meta-analysis
- Placebo effects and racial and ethnic health disparities: an unjust and underexplored connection
- Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice
- The nocebo effect
- Sharing online clinical notes with patients: implications for nocebo effects and health equity
- Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects
- Unethical informed consent caused by overlooking poorly measured nocebo effects
- Recommendations for the development, implementation, and reporting of control interventions in efficacy and mechanistic trials of physical, psychological, and self-management therapies: the CoPPS Statement
- Era of biosimilars in rheumatology: reshaping the healthcare environment